First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX)
| Market Cap | $1.75B+119.2% |
| Revenue (ttm) | $0 |
| Net Income | -$115.21M |
| EPS | -$3.27 |
| Shares Out | 42.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 504,364 |
| Open | $43.99 |
| Previous Close | $44.46 |
| Day's Range | $41.52 - $44.51 |
| 52-Week Range | $14.72 - $54.78 |
| Beta | 3.37 |
| Analysts | Buy |
| Price Target | $72.44(+73.97%) |
| Earnings Date | Feb 2, 2027 |
About TRAX
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyAnalyst consensus
6 firms rating TRAX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 2, 2027Earnings report
$TRAX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TRAX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TRAX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TRAX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TRAX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TRAX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TRAX
| VTIVanguard Morningstar Total Stock Market ETF | $40.72M |
| XBIState Street SPDR S&P Biotech ETF | $39.84M |
| IWMiShares Russell 2000 ETF | $38.97M |
| VXFVanguard Extended Market ETF | $15.59M |
| IWOiShares Russell 2000 Growth ETF | $9.76M |
| VTWOVanguard Russell 2000 ETF | $8.88M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TRAX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 5Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 2.12% |
| TDNA | T. Rowe Price Biotech ETF | 0.79% |
| HELX | Franklin Genomic Advancements ETF | 0.75% |
| OMFS | Invesco Russell 2000 Dynamic Multifactor ETF | 0.68% |
| SGRW | Harbor Active Small Cap Growth ETF (SGRW) | 0.66% |
| XBI | State Street SPDR S&P Biotech ETF | 0.43% |
| IWC | iShares Micro-Cap ETF | 0.42% |
| PJSM | PGIM Jennison Small-Mid Cap Core Equity ETF | 0.17% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.11% |
| ESLG | Eventide Large Cap Growth ETF | 0.09% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.09% |
| PWS | Pacer WealthShield ETF | 0.09% |
Weight is the stock’s share of each fund’s holdings.
